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Abstract 
Adverse drug reaction is defined by the World Health Organization as any response to a drug that is noxious and unintended and occurs 
at a dose normally used in man. Older people are at elevated risk of adverse drug reactions—because of changes in pharmacodynamics, con-
current use of multiple medications and the related drug interactions. However, adverse drug reactions are significantly underestimated in the 
elderly population that is also exposed to inappropriate drugs. Amiodarone is an antiarrhythmic drug used commonly for the treatment of 
atrial fibrillation and is increasingly prescribed in older people. While amiodarone is an efficient drug for rhythm control, it’s a carrier of 
different adverse reactions, and pro and cons must be carefully evaluated before its use especially in older people. 
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1  Introduction 
Amiodarone, a versatile class III antiarrhythmic drug, is 
considered one of the most effective agents in counteracting 
supraventricular and ventricular tachyarrhythmia. The drug, 
however, has a high toxicity profile involving diverse or-
gans. The World Health Organization (WHO) defines an 
ADR as “any response to a drug which is noxious and unin-
tended, and occurring at a dose normally used in man”.[1,2] 
ADRs, which are associated with the substantial expan-
sion in the use of medications,[3] increase the risk of death, 
the length of hospitalization, and the cost of care.[4]  
In the UK, ADRs are responsible for up to 6% of hospital 
admissions,[5] carry a mortality of 2%, and are associated 
with high costs. Similar ADRs hospital admission preva-
lence has been reported in studies conducted in Germany 
(6.5%)[6] and in Italy (6.1%).[7] 
Amiodarone is widely used in patients with atrial fibrilla-
tion (AF),[8] and it’s increasingly prescribed in elderly pa-
tients because of the increasing incidence of AF with age. 
Older people are at elevated risk of ADRs for changes in 
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pharmacodynamics, concurrent use of multiple medications 
and related interactions. 
 In this review, we focus on the pharmacology and ad-
verse reactions of Amiodarone. 
2  Amiodarone 
2.1  General characteristics 
Amiodarone (Figure 1) is an iodinated benzofuran de-
rivative, structurally similar to thyroid hormones, containing 
about 37% of organic iodine that is in part (> 10%) released 
as free iodide in vivo. The daily maintenance dose between 
100 and 600 mg, corresponding to 3.5–21 mg of iodine into 
the systemic circulation, equivalent to 35–140 fold excess of 
the iodine reference daily intake of 100–150 µg.[9] 
Amiodarone shows electrophysiological characteristics 
of all four Vaughan Williams classes.[10] The most important 
effect belongs to class III antiarrhythmic, i.e., prolongation 
of cardiac action potential time. Class I activity on fast so-
dium (Na+) channels is more pronounced at rapid heart rates. 
In addition, Amiodarone has antisympathetic properties 
(class II activity), because noncompetitively inhibits α- and 
ß-adrenergic receptors. It possesses negative chronotropic 
effects in nodal tissues (class IV activity) by L-type calcium 
(Ca2+) channel blockade. Amiodarone also inhibits myocar-
dial potassium (K+) channels. The anti-sympathetic activity  
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Figure 1.  Amiodarone and its metabolites in human plasma. 
and the blockade of Ca2+ and K+ channels slow the conduc-
tion and refractoriness in both the sinus and atrioventricular 
nodes.  
2.2  Pharmacokinetics and metabolism 
Oral Amiodarone has a slow and variable absorption rate, 
with a bioavailability of about 40%. After the first dose, the 
peak plasma levels are achieved in three to seven hours. The 
onset of action may take several days to a few weeks, thus 
loading doses help to achieve therapeutic levels more 
quickly. Plasma levels with repeated dosing at 100–600 
mg/day are approximately dose proportional, with a mean 
0.5 mg/L increase for each 100 mg/day. The steady-state 
plasma levels range 1.07–1.19 µg/mL but are up to 20 times 
more concentrated in the thyroid.[11] The bioavailability may 
be influenced by age, liver disease, and interactions with 
other drugs or substances that inhibit or induce cytochrome 
(CYP) 450, thus affecting efficacy. Amiodarone is a lipo-
philic drug, which absorption is enhanced if taken with 
foods high in fat content,[12] and has a large but variable 
volume distribution (66 L/kg of body weight). It accumu-
lates mainly in adipose tissue (from which it’s released very 
slowly) and in highly perfused organs such as liver, lung, 
and skin. Because of its long biological half-life of up to 
100 days, the activity may persist months after the interrup-
tion. About 10%–30% of Amiodarone crosses the placenta 
and a varying amount is excreted in breast milk.[10,13] 
Long-term oral treatment in a dose between 200 and 600 
mg/day has minimal effects on hemodynamics. It causes a 
dose-related negative inotropic effect through a reduction in 
systemic vascular resistance. Generally, it doesn’t have an 
effect on left ventricular ejection fraction and can be used 
safely even in patients with significant left ventricular dys-
function. Hypotension is rare during oral therapy (< 1%) but 
may occur in 16% of patients who receive intravenous 
treatment for refractory ventricular fibrillation or hemody-
namically unstable ventricular tachycardia.[10,13]  
Amiodarone is mostly eliminated through biliary excre-
tion in the gastrointestinal tract and minimally in urine. He-
patic metabolism proceeds mainly via N-dealkylation cata-
lyzed by CYPP450, specifically CYP3A4 and CYP2C8. 
Desethyl-amiodarone (Figure 1) shows a similar structure 
and electrophysiological activity, although less effective, of 
the parent drug.[14] Amiodarone inhibits p-glycoprotein and 
CYP450 enzymes that alter serum levels of other drugs or 
substances metabolized by these routes.[15]  
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Because of its water insolubility, Amiodarone is dis-
solved in polysorbate-80, a substance that may contribute to 
side effects of the commercially available compound, i.e., 
reduction in blood pressure, heart rate, depression of atrio-
ventricular node conduction, and increase in atrial and ven-
tricular refractory periods.[16]    
Upon infusion, a large percentage of Amiodarone binds 
to proteins, mainly to albumin and in a smaller percentage 
to beta-lipoprotein and alpha-1 acid glycoprotein.[17] Amio-
darone is a strong hepatic and renal metabolism inhibitor. It 
inhibits different cytochrome P450 pathways, including 
CYP2C9, which metabolizes warfarin, CYP2D6, which 
metabolizes several beta-blockers and narcotics, and CYP3A4, 
which metabolizes cyclosporine and calcium channel blo-
ckers.[18] The most clinically relevant interaction occurs with 
digoxin and warfarin. Concerning warfarin, the reduced 
clearance leads to an increase in prothrombin time and in-
ternational normalized ratio.[19] Digoxin levels double after 
Amiodarone co-administration, the result of P-glycoprotein 
transport system inhibition and consequent reduction in 
digoxin secretion from the renal tubules.[20] Therefore, it is 
recommended to halve digoxin dosage after the introduction 
of Amiodarone and to closely monitor plasma digoxin lev-
els. Patients treated with Amiodarone should avoid grape-
fruit or grapefruit juice because it could inhibit Amiodarone 
conversion to the active metabolite.[21] 
2.3  Indications 
2.3.1  Oral administration 
Oral Amiodarone was approved by the Food and Drug 
Administration (FDA) for the treatment of life-threatening 
and recurrent ventricular arrhythmias, such as ventricular 
fibrillation or ventricular tachycardia.[22] Prospective trials, 
in patients treated with Amiodarone after myocardial infarc-
tion with left ventricular systolic dysfunction, have shown 
improved survivability.[23,24] Despite these results, there is 
some evidence that Amiodarone could adversely affect sur-
vival in patients with New York Heart Association (NYHA) 
functional class III heart failure.[25] 
Implantable cardioverter-defibrillators are superior to 
Amiodarone in improving survival in patients with sus-
tained ventricular tachycardia or ventricular fibrillation due 
to a non-reversible cause, and in patients at elevated risk for 
sudden cardiac death, i.e., selected patients after myocardial 
infarction or with cardiomyopathy. The molecule is the 
first-line antiarrhythmic drug for patients with ventricular 
tachycardia or ventricular fibrillation who are not candidates 
for an implantable cardioverter-defibrillator (ICD).[26] Amio-
darone has been used up to 70% in patients with an ICD to 
reduce frequent arrhythmias related shocks. Moreover, it 
can be used also to suppress symptomatic, un-sustained 
ventricular tachycardia.  
Amiodarone is commonly used to treat AF although is 
not approved by the FDA for this purpose. The drug should 
be considered only after the failure of, or contraindications 
to, other medications because its potential organ toxicity. 
According to the American College of Cardiology (ACC)/ 
American Heart Association (AHA)/Heart Rhythm Society 
guidelines,[27] it can be used to maintain sinus rhythm in 
coronaropathy patients presenting heart failure, left ven-
tricular systolic dysfunction, left ventricular hypertrophy 
and/or drug-refractory symptomatic AF. Finally, some 
studies suggest that, Amiodarone may prevent AF related to 
cardiac surgery, but preoperative prophylaxis use is not 
universally accepted.[28]  
2.3.2  Intravenous administration 
Even though tissue levels rise rapidly, effective arrhyth-
mia suppression and prevention can take days or longer. 
Sinus bradycardia, atrioventricular blocks and torsade de 
pointes can occur after intravenous loading.[29]  
Intravenous administration is approved by FDA for the 
treatment and prophylaxis of recurrent ventricular fibrilla-
tion, hemodynamically unstable ventricular tachycardia, and 
to prevent ventricular fibrillation or tachycardia in patients 
candidate to oral Amiodarone but unable to take the oral 
preparation.[30]  
Based on the 2010 American Heart Advanced Cardiac 
Life Support guidelines, intravenous administration is the 
first choice for persistent ventricular fibrillation or pulseless 
ventricular tachycardia resistant to other resuscitative meas-
ures including epinephrine.[28] Amiodarone can be used to 
treat lidocaine-refractory ventricular tachycardia or ven-
tricular fibrillation after acute myocardial infarction, “elec-
trical storm” (multiple episodes of recurrent rapid ventricu-
lar tachycardia or ventricular fibrillation requiring multiple 
shocks over a brief time period), and non-sustained and re-
current ventricular tachycardia in patients with implantable 
cardioverter-defibrillators who experience frequent device 
shocks.[31] 
The drug administered intravenously can treat also su-
praventricular, most commonly acute-onset AF, including 
perioperative cardiovascular surgery, in intensive care units, 
and in emergency departments. Although it can slow the 
ventricular response during acute-onset AF, it is not ap-
proved by FDA for this purpose.[32]  
In placebo-controlled trials, intravenous Amiodarone has 
not been shown to convert AF acutely.[32] Although, it can 
reduce the occurrence of AF after cardiac surgery, a reduc-
tion in the length of hospital stay and adverse outcomes has 
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not been demonstrated yet.[33] Intravenous Amiodarone is 
reported to induce heart block or bradycardia in 4.9% of 
patients, and hypotension in 16%.  
2.4  Contraindications 
Amiodarone is contraindicated in patients with cardio-
genic shock, severe sinus-node dysfunction, marked sinus 
bradycardia, second- or third-degree atrioventricular block, 
and syncope related to bradycardia. It is contraindicated in 
patients with a known hypersensitivity to the drug or to any 
of its components, including iodine.[34] 
3  Side effects and adverse reactions 
3.1  Cardiac adverse reactions  
Amiodarone could impair sinus beat formation and con-
duction and may induce significant bradycardia, especially 
in patients with pre-existing conduction disorders, and marked 
prolongation of the QT interval. These events are due to its 
effect in blocking the potassium channels. This mechanism, 
moreover, can lead to dangerous polymorphic ventricular 
arrhythmia or torsade de pointes.[35] Physicians should be 
aware that QT elongation can be favoured temporary in 
patients on Amiodarone therapy, like severe lung disease, 
hypertension, concomitant antiarrhythmic drugs, antibiotics, 
antipsychotics, and anti-depressive drugs (Table 1).  
Stramba-Badiale, et al.[36] reported that female gender 
may play a role in the occurrence of QT interval prolonga-
tion because sex steroid hormones may influence ventricular 
repolarization. In accord to this hypothesis, prolongation of 
QT interval during Amiodarone treatment in the female 
patients is found only after puberty. Notwithstanding, 
Amiodarone appears to have the lowest pro-arrhythmic ac-
tion compared to other antiarrhythmic agents. The reason 
for the low incidence of pro-arrhythmia remains unclear but 
it’s probably multifactorial.[37] Moreover, drug-induced QT 
prolongation most commonly occurs in patients with sub-
clinical mutations in one of the genes causing the congenital 
long QT syndrome. In fact, the allelic variants of the coding 
region of congenital long QT syndrome, can be identified in 
10 to 15% of patients with Amiodarone induced QT pro-
longation.[38] 
Antonelli, et al.[39] showed that these patients are at higher 
risk of torsade de point after potassium channels blocking 
drugs administration, such as Amiodarone. Early episodes 
of torsade de point in patients on oral low dose (200 
mg/day), in the absence of other predisposing factors, em-
phasize the importance of a careful patient monitoring. 
Isoproterenol infusion is the drug of choice to increase 
the heart rate and to shorten the QT interval in patients with 
Amiodarone-associated symptomatic bradycardia and/or 
prolonged QT interval. 
Amiodarone acutely infused intravenously can provoke 
hypotension by inducing vasodilation and depression of 
myocardial contractility. Curiously, this mechanism has 
been proposed to be more related to the eccipient polysor-
bate 80 or benzyl alcohol than Amiodarone itself.[40] In ac-
cord, experimental studies have shown that hypotension is 
not observed when is Amiodarone is dissolved in cyclodex-
trin.[40] Amiodarone may also cause signs and symptoms of 
allergic reactions, including angioedema, urticarial rash or 
even anaphylactic reactions that rapidly improve after drug 
discontinuation.[34] 
3.2  Ocular adverse reactions  
Ocular alterations represent the most frequent side effect 
of Amiodarone. Among this group can be found a wide 
spectrum of abnormalities. Typically, Amiodarone, can led 
to corneal microdeposits (up to 98%), corneal opacities, 
lenticular changes, loss of eyelashes or eyebrows, papille-
dema, photosensitivity, scotoma, macular degeneration and 
optic neuropathy or optic neuritis.[41]  
Symmetrical microdeposits in the granular corneal epi-
thelium, anterior to Bowman's membrane, occurs early and 
are found in nearly 100% after 1 to 2 months of treatment.[42] 
Asymptomatic corneal opacities are present in 50%60% of 
patients. However, these changes do not affect eyesight and 
drug discontinuation is not warranted.[43] Retinopathy has 
rarely been reported.[44] Clinical findings of optic neuropa-
thy share features with non-arteritic anterior ischemic optic 
neuropathy (NAION), the most common cause of visual 
loss from optic nerve disease among individuals over the 
age of 50.[45] 
Mindel, et al.[46] presented the largest study with the aim 
to associate Amidoarone and vision loss. In their study, 
1600 patients for up to 45.5 months, failed to find an asso-
ciation between Amiodarone and bilateral toxic vision loss. 
However, it must be considered that in this study, patients 
did not go through an ophthalmologic evaluations, but just 
through a nurse’s query on “optic neuritis”, making unilat-
eral or mild bilateral visual loss go undetected.  
Recently, Passman, et al.[47] retrieved data from the FDA 
Adverse Event Reporting Systems and found 296 cases of 
optic neuropathy associated with drug therapy. Mansour, et 
al.[48] identified multiple lamellate inclusion bodies in large 
axons of the optic nerve, while demyelination or loss of 
large axons was not seen. Meanwhile, demyelination, loss 
of large axon and lamellate bodies are seen in the neurons 
and the Schwann cells of peripheral nerves in Amiodar-
one-associated peripheral neuropathy.[49,50] Lamellate bodies 
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deposits have been attributed to inhibition of lysosomal 
sphingomyelinases, but it’s not clear whether histopa-
thological differences are due to the type of cell or differ-
ences in the time course of ocular versus peripheral neu-
ropathy findings before clinical symptoms develop.[44] 
Amiodarone induced optic neuropathy and NAION dif-
fer with respect to optic disk appearance on funduscopic 
examination, sex distribution, laterality, and duration of disk 
oedema. Amiodarone-induced optic neuropathy occurs 
more often in men, tends to be insidious in onset, and two 
third of cases show bilateral involvement.[47] On the other 
hand, NAION tends to be equally sex distributed it appears 
often on acute onset, unilaterally, and resolves within 
weeks.  
Moreover, whereas NAION occurs more often in patients 
with a small optic nerve cup-disk ratio, there is no particular 
cup-disk ratio associated with Amiodarone associated optic 
neuropathy.[51,52] 
Doubts can be related to the fact that many patients have 
concurrent therapy, more often with digoxin that, enhanced 
by Amiodarone, can decrease vision and alter colour per-
ception, presumably as a result of optic nerve damage.[53] 
Ocular toxicity generally occurs within one year after start-
ing the drug, with a median time to onset of visual symp-
toms within six months.  
The National Institute for Health and Clinical Excellence 
guidelines for AF recommended Amiodarone use but are 
silent on recommendation relative to monitoring side effects. 
The Heart Rhythm Society[54] recommends an ophthalmo-
logic evaluation for patients with pre-existing visual im-
pairment or during follow-up if visual symptoms develop. 
Johnson, et al.[52] suggest equally spaced interval evalua-
tions within the first year, followed by annual examinations 
to evaluate Amiodarone-induced optic neuropathy. When 
ocular toxicity is suspected it should be confirmed by oph-
thalmologic findings and reported to the appropriate sur-
veillance system.  
3.3  Pulmonary adverse reactions 
3.3.1  Epidemiology and Incidence  
Until 1980, there were no reports in the literature of 
pulmonary toxicity due to Amiodarone despite its wide-
spread use since its introduction in the market in 1967. 
Rotmensch, et al.[55] hypothesized that the drug could have 
been responsible for pulmonary infiltrates in one of their 
patients. Afterward, Sobol, et al.[56] reported six cases of 
potential Amiodarone pulmonary toxicity (APT). All the 
reported patients showed interstitial fibrosis and pneumonia, 
and none had clear predisposing factors or pathologic find-
ings indicative of an identifiable etiology. The risk of toxic-
ity with Amiodarone increases with the total cumulative 
dose rather than with the daily dose or plasma concentra-
tion.[57] Although toxicity can occur at any time after treat-
ment is initiated, patients considered at greatest risk are 
whose have received a daily dose of 400 mg or more for 
more than two months or a lower dose, commonly 200 mg 
daily, for more than two years.[58]  
In the earliest descriptions of APT, when patients were 
usually taking 400 mg or more per day, the reported inci-
dence of APT was between 5% and 15%.[59,60] A lower rate 
of APT (1.6%) resulted in patients receiving daily Amio-
darone doses of 400 mg or less.[61] Consistently, 
Goldschlager, et al.[62] reported an estimated rate of 2%. 
Polkey, et al.[63] emphasized hat there is probably no ‘safe’ 
dose of this medication, and this complication continues to 
be reported. Thus, Ott, et al.[64] noted eight cases of APT in 
patients receiving 200 mg/day, the dose most commonly 
used in clinical practice. These authors underlined the need 
for vigilance even with ‘low-dose’ Amiodarone therapy. 
Other conditions that increase the risk of pulmonary toxicity 
include age, pre-existing lung disease and/or an abnormal 
chest X-ray before starting treatment.[58] Furthermore, pa-
tients undergoing surgery and/or pulmonary angiography 
while on Amiodarone therapy have an increased risk for 
developing pulmonary adverse effects.[65] The latency time 
for the appearance of pulmonary toxicity is variable, usually 
from a few months to a year.[66] In rare cases, it can also 
develop from a few weeks to months after discontinuation 
of treatment. Acute respiratory distress syndrome (ARDS) 
attributable to treatment with Amiodarone has been de-
scribed after general surgery, cardiac surgery, and thoracic 
surgery.[65] Jackevicius, et al.[67] presented a retrospective 
study, enrolling 57,393 patients with AF older than > 65 
years, in order to investigate the risk of developing 
Amiodarone induced pulmonary toxicity (APT). The study 
showed that APT occurred in 250 of 6460 Amiodarone us-
ers (3.87%) and 676 of 50,993 nonusers (1.33%). From their 
results, it’s found a nearly threefold higher crude incidence 
of APT in “users” compared to “nonusers”. The incidence 
of about 4% APT was in agreement with the rate of 10% 
reported by previous studies.[67] The risk was greater in men 
(nearly up to 40% increased risk of APT in men versus 
women), older patients, and those with chronic obstructive 
pulmonary and kidney disease. 
3.3.2  Pathogenesis 
The side effects of Amiodarone, including its main deri-
vate desethyl-amiodarone seems related the highly lipo-
philic characteristics and the concurrent long half-life, 
which is wide variable (35100 days), and accumulation in 
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the different tissues of the body, including the lung.[68] Al-
though still uncertain, the pathogenesis of lung injury seems 
to be a direct toxic effect on the turnover of intracellular 
phospholipids.[60] In patients with APT, tissue sections show 
infiltration of polymorphonuclear cells and lymphocytes, as 
a proof of inflammation and a possible immune reaction to 
the drug.[60] Jessurun, moreover, showed type II Pneumo-
cytes hyperplasia and widening of alveolar septa with vary-
ing degrees of interstitial fibrosis.[59] A typical finding is the 
accumulation of lipid-laden macrophages in the alveolar 
space. Ultrastructural examination of these cells shows 
membrane-bound lamellar bodies similar to surfactant.[69] It 
should be noted, however, that foamy macrophages, some-
times with lamellate inclusion bodies, have been reported in 
patients receiving chronic Amiodarone therapy in the ab-
sence of APT.[70] Bronchoalveolar lavage fluid is reportedly 
containing cytotoxic T cells supporting a role of an im-
mune-mediated reaction playing a role in APT.  
In some cases, there is little evidence of an inflammatory 
process and the predominant finding is nonspecific pulmo-
nary fibrosis. This may be found after an acute episode of 
typical APT or diagnosed lately in latent forms.[71] On light 
microscopy, vacuolization of the cytoplasm is seen in al-
veolar Pneumocytes, bronchial epithelial cells, and endothe-
lial cells.[69,72] Less frequent pathological manifestations of 
APT include patchy bronchiolitis, obliterans organizing 
pneumonia or a severe diffuse alveolar damage with hyaline 
membrane formation.[73] 
3.3.3  Clinical and lab findings 
The patterns of lung involvement in patients with APT 
are variable and include chronic interstitial pneumonia with 
or without fibrosis, bronchiolitis with or without organizing 
pneumonia, and ARDS. Individuals usually present with 
progressive shortness of breath, non-productive cough, mal-
aise, fever, and occasionally pleuritic chest pain.[59,64,73] 
Physical examination may be unremarkable in milder cases, 
but in more severely affected individuals, diffuse rales, hy-
poxemia, and respiratory distress may be noted. Having no 
clinical and histological features, the diagnosis of APT is of 
exclusion. Laboratory data may reveal a leucocytosis that is 
rarely due to eosinophilia. A nonspecific elevation in lactic 
dehydrogenase or serum KL-6, a mucin-like glycoprotein, is 
often present but does not distinguish APT from other inter-
stitial lung diseases.[73,74]  
Pulmonary function tests usually reveals low lung volu-
mes and a restrictive pattern in these patients. The diffusion 
lung capacity for carbon monoxide (DLCO) should always 
be performed before starting therapy, particularly in patients 
with previous lung disease. In fact, an isolated, small reduc-
tion in DLCO is present in most patients in chronic therapy, 
and it should not be considered a sign of pulmonary toxicity 
but of drug exposure.[75,76] This is attributed to an increase 
in phospholipids and pulmonary surfactant. The Conges-
tive Heart Failure-Survival Trial of Antiarrhythmic Therapy 
study,[75] reported a reduction in DLCO by 6% after 1 year 
of treatment with Amiodarone, compared to patients treated 
with placebo (P = 0.02). In the subgroup of patients with 
COPD, the DLCO was reduced of 11.4% versus no varia-
tions in patients treated with placebo. This finding high-
lights the toxicity of the drug that increases in the presence 
of lung injury.  
Moreover, these patients can develop different degrees of 
hypoxemia related their chronic lung disease worsened by 
the Amiodarone pulmonary toxicity.  
3.3.4  Radiographic features 
High-resolution computed tomography (HRCT) scanning 
has greater sensibility than chest X-ray to highlight the 
pulmonary injury. The HRTC images usually reveal bilat-
eral interstitial, alveolar, or mixed interstitial and alveolar 
infiltrates.[77] Pleural thickening is commonly seen, espe-
cially in areas where the infiltrates are densest, while pleural 
effusion is a less common finding. High attenuation may be 
noted incidentally during HRCT on views of the liver and 
spleen, related to the accumulation of Amiodarone and its 
metabolites in tissue macrophages. This latter finding is not 
necessarily associated with APT. 
Gallium scanning might demonstrate increased, non- 
specific, parenchymal activity and may help to differentiate 
infiltrates from oedema due to congestive heart failure, a 
condition frequently present in patients taking Amiodar-
one.[78] A more unusual radiographic finding in patients with 
APT is the presence of single or multiple pulmonary nod-
ules, or mass-like opacities.[27] They are most often seen in 
the upper lobes, frequently peripherally adjacent to the 
pleura. These nodules are due to localized drug deposits in 
areas of previous inflammation and usually have high at-
tenuation for the presence of iodine-rich Amiodarone in 
type II pneumocytes within the lesions.[79,80] It is important 
to know that these nodules/masses have increased uptake on 
fluorodeoxyglucose positron emission tomography scanning, 
falsely suggesting a lung neoplasm.[81] The most dramatic 
manifestation of APT is a rapidly progressing diffuse pneu-
monitis with acute respiratory failure and features typical of 
ARDS. This condition has been reported after contrast in-
fusion for pulmonary angiography, and particularly in pa-
tients undergoing cardiac or pulmonary surgery, especially 
pneumonectomy.[73,79,82] Van Meighen, et al.[30] reported an 
incidence of ARDS of 11% after pulmonary surgery in pa-
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tients treated with Amiodarone, compared with 1.8% in 
those without. Susceptibility to Amiodarone-induced lung 
damage may be particularly relevant in patients undergoing 
major cardiothoracic surgery, in relation to the presence of 
chronic lung disease and the concomitant use of mechanical 
ventilation in the perioperative period. Moreover, some au-
thors hypothesized that Amiodarone is a potential, unrecog-
nized cause of acute respiratory failure in the intensive care 
units.[82] These data suggest that physicians should careful 
doublethink of starting Amiodarone in such a high risk 
population as chronic lung disease patients.  
3.3.5  Diagnosis 
The Amiodarone pulmonary toxicity must be considered 
for all patients treated with Amiodarone presenting new or 
worsening pulmonary symptoms such as a non-productive 
cough, shortness of breath, malaise, fever, pleuritic chest 
pain, and new infiltrates on chest X-ray.[73] The physical 
examination often reveals bilateral inspiratory crackles.[83] 
In most cases, the diagnosis is made by exclusion because 
these patients often have associated morbidity that exposes 
them to the risk of pulmonary oedema, pneumonia, pulmo-
nary embolism or other acute events, which complicate the 
diagnosis. Isolated, small reduction in DLCO without clini-
cal evidence of disease is not specific and not diagnostic for 
APT.[84] Fibre optic bronchoscopy with bronchoalveolar 
lavage (BAL) and transbronchial biopsy can be extremely 
useful in ruling out other causes of diffuse lung disease. 
BAL cells may reveal evidence of an inflammatory or im-
mune response,[59,52] but is not diagnostic for Amiodarone 
toxicity. Thus, total or differential BAL cell count, while 
they may suggest the presence of pneumonitis, do not allow 
Amiodarone to be directly implicated. Likewise, lung bi-
opsy, though it may be helpful and may show a characteris-
tic lipoid pneumonitis, is more often non-diagnostic and 
may reveal just aspecific inflammatory changes.[85] Plasma 
levels of Amiodarone are non-diagnostic, but elevated levels 
of its metabolite, desethyl-amiodarone, have been found to 
be more frequent in patients with a diagnosed pulmonary 
toxicity.[86] 
3.3.6  Treatment 
Once the diagnosis of APT is considered plausible, the 
drug should be discontinued. After that, clinical and radio-
logical improvement can be slow in relation to the long 
half-life of the accumulated drug in the lung. It has been 
suggested that the more insidious the onset of the disease, 
the slower the resolution.[59] The general consensus is that 
corticosteroid should be given to patients showing extensive 
involvement on imaging or hypoxemia in the attempt to 
accelerate the recovery process and possibly to minimize the 
likelihood of lung fibrosis.[83] Prednisone is started at doses 
of 40 mg/day to 60 mg/day orally and tapered slowly. Again, 
the pharmacodynamics of Amiodarone dictates treatment 
for 4 to 12 months.[58] Cases of relapse on early steroid 
withdrawal have been reported. Okayasu, et al.[87] suggested 
that patients with excess adipose tissue, as measured by a 
high body mass index, are more susceptible to recurrences 
with steroid tapering because of the high concentration of 
lipophilic Amiodarone within their adipocytes.  
Things get complicated when patients develop APT and 
are unable to take off Amiodarone due to the complexity of 
the arrhythmias. Zaher, et al.[88] proposed that an APT 
evaluation should take place in order to understand its se-
verity in these patients. No life-threatening, and Amio-
darone alternative is to reduce the dosage to the minimum 
effective dose in association with low-dose of steroids.  
3.3.7  Screening and follow-up 
Recommendations to reduce the risk of Amiodarone tox-
icity suggest chest X-ray and pulmonary function tests, in-
cluding DLCO, obtained before therapy and a yearly chest 
X-ray as long as patients remain on Amiodarone treat-
ment.[61] An immediate chest X-ray and pulmonary function 
testing should be performed if there is clinical suspicion of 
pulmonary toxicity.  
3.3.8  Prognosis 
When diagnosed early, the prognosis of Amiodarone-re-
lated lung disease is usually favourable. However, the more 
advanced disease may be fatal or result in pulmonary fibro-
sis.[58] Clinical improvement and clearing of pulmonary 
opacities typically require 1–3 months.[83] Radiological fol-
low-up shows complete clearing in about 85% of patients 
while residual opacities persist in the remaining patients.[89] 
A mortality rate of 5%10% due to pulmonary has been 
attributed to Amiodarone doses hiogher than 400 mg/day.[59] 
Yet in patients who develop acute respiratory distress syn-
drome and require mechanical ventilation, mortality is as 
high as 50% to 100%.[90] 
3.4  Hepatotoxicity due to intravenous Amiodarone 
Infusion 
Approximately 25% of patients taking Amiodarone de-
velop a transient asymptomatic rise in serum aminotrans-
ferase levels. Symptomatic hepatitis, cirrhosis, and hepatic 
failure are less common complications that involve less than 
3% of patients under Amiodarone chronic, oral treatment.[91] 
Amiodarone-associated hepatitis shares histological features 
with alcoholic hepatitis and includes steatosis, fibrosis, and 
Biancatelli RMC, et al. Amiodarone side effects 559 
  
http://www.jgc301.com; jgc@jgc301.com | Journal of Geriatric Cardiology  
phospholipid laden lysosomal lamellar bodies.[92] Hepatitis 
due to intravenous Amiodarone infusion (HIVAD) is ex-
tremely rare and only 34 cases, of which six, have been re-
ported in the literature.[93] The pathophysiological mecha-
nism is still unknown. HIVAD shares many characteristics 
that are seen in ischemic hepatitis. Gluck, et al.[94] proposed 
that acute liver injury is related to liver ischemia, rather than 
direct drug toxicity. The majority of cases reported in the 
literature show evidence of poor forward output, hepatic 
venous congestion, impaired circulation, and acute kidney 
injury that in turn facilitate ischemic hepatitis. Drug infusion 
is associated with elevation of transaminases within 24 h. 
The role of polysorbate 80, which is used to solubilize 
Amiodarone for i.v. use, cannot be excluded.[95] Polysorbate 
80 has been implicated in the E-ferol syndrome, described 
in infants, characterized by hepatomegaly, splenomegaly, 
cholestatic jaundice, renal failure, and thrombocytopenia. 
Liver histology of this syndrome shows Kupffer cell exfo-
liation, centrilobular accumulation of cellular debris, and 
panlobular congestion.[96] Lahbabi, et al.[95] published a case 
report of acute hepatitis during Amiodarone infusion but 
showing normalization of liver function tests thereafter dur-
ing oral Amiodarone treatment. This observation supports 
the concept that HIVAD could be related to the diluent 
rather than the drug. 
Whatever the cause of HIVAD, physicians should be 
aware of this possible mechanism and regularly obtain a 
liver function panel subsequent to parenteral drug infusion, 
and proceed with caution in the setting of heart failure and 
hepatic congestion. The role of polysorbate in inducing the 
acute liver effects could not be excluded.[97] 
3.5  Amiodarone-induced dermatologic side effects 
Dermatologic side effects include photosensitivity 
(24%–57%) and blue-gray skin discoloration (1%–7%).[98] 
The mechanism of the reaction seems to be related to the 
active metabolites generated by UV radiation and oxygen 
free radicals. Phototoxic effects of Amiodarone and dese-
thyl-amiodarone were shown in vitro tests related to the use 
of photohemolysis, DNA synthesis inhibition assay in phy-
tohaemoagglutinin-stimulated lymphocytes and finally the 
killing of macrophages obtained from mouse peritoneal 
fluid.[99] Skin lesions, which usually occur after at least four 
months of therapy and with the minimal cumulative dose of 
40 g,[100] are typically erythematous or eczematous in ap-
pearance, iching and sun exposed areas, i.e., hands, face, 
and neck. Rare cases of toxic epidermal necrolysis, exfolia-
tive dermatitis, vasculitis, polyserositis, bullous dermatosis, 
and pustular psoriasis have also been described.[101]   
Few cases of Amiodarone-induced air-loss and alopecia 
have been reported in the literature.[102] Samanta, et al.[103] 
described a case of complete alopecia resolving eight 
months after Amiodarone discontinuation. Despite this side 
effect is considered to be very rare, it has been supported by 
two studies where drug re-challenge led to the recurrence of 
alopecia.[104] Although alopecia doesn’t seems to be the 
most dangerous side effects of Amiodarone, it can be related 
to a reduction in self-confident through psychological issue 
that can be even be worse in female patients. 
3.6  Amiodarone induced epididymitis  
About 20 cases of Amiodarone-induced epididymitis have 
been reported.[105,106] Amiodarone-induced epididymitis is a 
chronic condition that usually appears bilaterally without 
fever or leucocytosis. In these patients, discrete amount of 
Amiodarone metabolites have been found toaccumulate 
locally. Histological examination reveals focal epididymal 
fibrosis and lymphocyte infiltration.[105] The time course of 
drug therapy and the reported urological symptoms varies 
from 4 to 71 months.[107] These symptoms can resolve upon 
Amiodarone discontinuation within 10 days to 3 months. 
Finally, in patients unresponsive to painkiller and unable to 
discontinue medication epididymectomy could be con-
sidered.[108] 
3.7  Hematological side effects 
Pancytopenia, hemolytic anaemia, and aplastic anaemia 
are rare hematologic side effect reported in patients on 
Amiodarone. Ten cases of bone marrow granulomas have 
been reported in the literature.[109,110] These patients–pre-
senting with severe thrombocythemia, paraproteinemia, and 
anemia or pancytopenia, underwent bone marrow biopsy 
that revealed normocellular marrow with multiple non-ca-
seating granulomas negative for acid-fast bacteria and 
fungi.[111] No data were presented about discontinuation and 
rechallenge, but the time on medication and the absence of 
other possible ematological causes, led to be amidoarone the 
first suspect. Physicians should consider Amiodarone as a 
cause of bone marrow granuloma in patients taking this 
antiarrhythmic drug and presenting with cytopenia.[110]  
3.8  Psychiatric side effects 
Only few cases of altered mental status[112] related to 
Amiodarone therapy have been reported. These cases in-
cluded catatonic depression,[113] hallucinations and delir-
ium.[114] Although the prevalence of this disorder is ex-
tremely low, it is worthy of note the time-dependent relation 
between the onset of therapy and the beginning of psychiat-
ric symptoms. Barry, et al.[115] reported a case in which 
symptoms appeared after four days of Amiodarone therapy, 
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decreased after discontinuation, and appear again after four 
days re-challenge. Despite the casuistry is very small, dis-
continuation and re-challenge are the strongest factors to 
ADR diagnosis.  
Moreover, it has been reported that blood drug concen-
tration is associated to neuropsychiatric disorders like, 
tremor, asthenia, hallucinations, and agitation.[112] The effects 
of Amiodarone on thyroid functionality could explain the 
humour variability seen among different patients. However, 
the few cases of Amiodarone-induced catatonic depression 
presented with poorly increased TSH levels are not enough 
to justify this theory.[113] Delirium and altered mental status 
are frequent features of in-hospital, chronic heart disease old 
people. These patients are the best candidates to start oral 
Amiodarone therapy.  
It is plausible to think, that new Amiodarone medication 
could have led to plenty of undiagnosed in-hospital altered 
mental status.  
3.9  Amiodarone induced neuromuscular disorders 
Amiodarone-induced neurologic side effects have a 
prevalence of 3%30%[58] include tremor, ataxia, peripheral 
neuropathies, gait disturbances, myopathies, paraesthesia, 
vestibulopathies and insomnia.[44,48,116] Flanagan, et al.[117] 
reported that patients with neuro-myopathy showed clinical 
features of proximal and distal muscle weakness, dysphagia, 
ataxia, and poly-myoclonus. Electromyography revealed 
short duration, low amplitude, rapidly recruited motor unit 
potentials in the proximal muscles. Muscle biopsies re-
vealed features of necrotizing myopathy and vacuolar 
myopathy. After Amiodarone discontinuation, patients im-
proved in 26 months, with a decrease in creatine kinase 
blood levels. Amiodarone is an amphiphilic cation and 
could interact with anionic phospholipids of organelles, 
which may predispose to the formation of autophagic vacu-
oles seen in muscle biopsies; meanwhile, its metabolite de-
sethyl-amiodarone may accumulate in muscle tissue.[118] In 
the study of Abarbanel, et al.,[49] Amiodarone therapy was 
associated to a peripheral neuropathy characterized by de-
myelination, loss of large axons and deposits of lamellated 
bodies, attributed to inhibition of lysosomal sphingomyeli-
nases. 
3.10  Thyroid adverse effects 
Thyroid adverse effects related to chronic Amiodarone 
therapy are frequent. Functional thyroid disorders are 
caused by its high iodine contents, that is 37 mg/100 mg, 
whose 10% is available for metabolic processes of deiodi-
nation.[119] Thyroid abnormalities have been reported in up 
to 14%18% of patients receiving long-term Amiodarone 
therapy.[120] Based on a meta-analysis, Amiodarone lower 
oral dose (150330 mg) is associated to thyroid dysfunction 
in 3.7% of patients.[13] The clinical presentation may reveal 
hyperthyroidism, which is more frequent in geographical 
areas with low iodine intake, such as Europe - or hypothy-
roidism, which is more frequent in iodine-replete areas, such 
as the United States.[13,120,121] 
Amiodarone is recognized to act at different enzymatic 
and non-enzymatic levels in the thyroid:[122]  
It inhibits type 1 5'-deiodinase enzyme activity thereby it 
decreases the peripheral conversion of thyroxine (T4) to 
triiodothyronine (T3) and reduces the clearance of both T4 
and reverse-T3. Consequently, the serum levels of T4 and 
rT3 increase and the serum levels of T3 decrease by 
20%25%.  
Amidoarone, inhibits type 2 5'-deiodinase enzyme activ-
ity in the pituitary gland due to feedback regulation. It oc-
curs in the first 1-3 months of therapy and leads to an in-
crease in thyroid-stimulating hormone (TSH) levels. This is 
not an indication for T4 replacement in these patients. Serum 
TSH levels are normalized in 23 months when T4 concen-
tration rises sufficiently to overcome the partial block in T3 
production. 
It inhibits entry of T4 and T3 into the peripheral tissue.  
Serum T4 levels increase by an average of 40% above pre- 
treatment levels after 14 months of treatment with Amio-
darone, but it does not constitute evidence of hyperthy-
roidism. T4 levels can be clearly elevated or at the upper 
limit of normal range. 
Amiodarone and its metabolites show a direct, dose-de-
pendent cytotoxic effect on the thyroid follicular cells, by an 
iodine-independent mechanism, causing destructive thyroi-
ditis consisting in areas of necrosis, macrophage infiltrations, 
and inclusion bodies. These effects are present also in other 
organs, such as liver, skin, lung, heart, cornea and peripheral 
nerves. Amiodarone and its mean metabolically metabolite 
desethyl-amiodarone can act as a competitive antagonist of 
T3 on the cardiac cells. 
The excess of iodine caused by Amiodarone inhibits 
thyroid hormone synthesis, leading to hypothyroidism in 
through the Wolff-Chaikoff effect. 
Amiodarone and desethyl-amiodarone block T3 binding 
to nuclear thyroid receptors and decrease expression of 
some thyroid hormone-related genes such as α-myosin 
heavy chain and the low-density lipoprotein receptor. In 
summary, serum T4 levels rise by 20%40% during the first 
month of therapy and then gradually fall toward high nor-
mal. Serum T3 levels decrease by up to 30% within the first 
few weeks of therapy and remain slightly decreased or low 
normal. Serum rT3 levels increase by 20% soon afterward 
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and remain increased. Serum thyrotropin (TSH) levels usu-
ally rise after the start of therapy but return to normal in 23 
months. 
The most likely mechanism of Amiodarone-induced hy-
pothyroidism (AIH) is an increased susceptibility to the 
inhibitory effect of iodine and the inability of the thyroid 
gland to escape from the Wolff-Chaikoff effect after an io-
dine load in patients with pre-existing Hashimoto thyroiditis. 
In addition, iodine-induced damage to the thyroid follicles 
may accelerate the natural trend of Hashimoto thyroiditis 
toward hypothyroidism. It is likely that patients without 
underlying thyroid abnormalities have subtle defects in io-
dine organification that lead to decreased thyroid hormone 
synthesis, peripheral down-regulation of thyroid hormone 
receptors, and subsequent hypothyroidism. 
3.10.1  Amiodarone induced thyrotoxicosis 
Amiodarone-induced thyrotoxicosis (AIT), contrarily to 
spontaneous hyperthyroidism, is more common in men than 
in women,[10] with a male-to-female ratio of 3: 1. Although 
Amiodarone-induced hypothyroidism poses no particular 
problem, Amiodarone-induced thyrotoxicosis is a diagnostic 
and therapeutic challenge. There are two main forms of AIT: 
(1) type 1, an iodine-induced hyperthyroidism, that usually 
occurs in abnormal thyroid glands; (2) and type 2, a drug-in-
duced destructive thyroiditis, that develops in apparently 
normal thyroid glands (or small goiters) and that leads to the 
release of preformed thyroid hormones from the damaged 
thyroid follicular cells.[10] AIT can develop early or late 
during Amiodarone treatment, or even several months after 
drug withdrawal.[123] Total body iodine stores do not de-
crease up to 9 months after drug discontinuation. Type 2 
AIT is associated with increased mortality risk, especially in 
elderly patients with impaired left ventricular function.[124] 
The onset of AIT is often sudden and explosive and may 
occur early after starting Amiodarone. AIT might present 
heavily symptomatic, especially in younger patients, whose 
clinical manifestations are indistinguishable from those of 
spontaneous hyperthyroidism. It’s crucial to promptly iden-
tify the two subtypes of AIT and start appropriate therapeu-
tic approach.[125] Classical symptoms may be absent for the 
anti-adrenergic action of drug and the impairment of T4 to 
T3 conversion, and the syndrome can be afforded after 
worsening of the underlying cardiac disorder, with occur-
rence of heart failure, tachyarrhythmias, angina, and 
weight loss.[10,126]   
Thyroid ultrasonography shows the presence or absence 
of a diffuse or a nodular goiter. Color flow doppler sono-
graphy (CFDS) of the thyroid is an important diagnostic 
tool to differentiate the two subtypes because type 2 AIT is 
characterized by absent hypervascularity (pattern 0), instead 
in type 1 usually there is an increased vascularity (patterns 
1–3) and blood flow velocity.[127] 
Search for thyroid-directed auto-antibodies, particularly 
TSH receptor autoantibody, is relevant only in AIT patients 
with an underlying and pre-existing Graves’ disease. 
3.10.2  Amiodarone induced hypothyroidism 
Amiodarone-induced hypothyroidism (AIH) occurs more 
frequently than AIT in iodine-sufficient areas. In contrast to 
AIT, AIH is slightly more frequent in female patients, fe-
male to male ratio of 1.5: 1, who are older than AIT patients. 
AIH usually develops earlier than AIT, both in patients with 
apparently normal thyroid glands and in patients with 
pre-existing thyroid abnormalities.[10] The most frequent 
pre-existing abnormality is the presence of circulating thy-
roid peroxidase antibodies. It has been reported that the 
combination of female sex and antithyroid antibodies in-
crease 13.5 times the risk of AIH.[128] Thus, pre-existing 
Hashimoto’s thyroiditis is an established risk factor for the 
occurrence of hypothyroidism in Amiodarone-treated pa-
tients that have an enhanced susceptibility to develop 
myxedema. It is also possible that the cytotoxicity induced 
by Amiodarone would decrease the possibility of a devel-
oping goiter while receiving Amiodarone.[129] 
The most likely pathogenic mechanism is that the thyroid 
gland of these patients, damaged by pre-existing Hashi-
moto’s thyroiditis, is unable to avoid the acute Wolff- 
Chaikoff effect after iodine load and to resume normal thy-
roid hormone synthesis for a subtle defect in thyroid hor-
monogenesis.[130] This is supported by a positive perchlorate 
discharge test, indicating a defect in iodine organification. 
In addition, AIH accelerates the natural trend of the 
pre-existing Hashimoto’s thyroiditis toward hypothyroid-
ism.[130] It has been reported that AIH may spontaneously 
remit. Clinically, AIH is very similar to spontaneous hypo-
thyroidism and arises with vague symptoms and signs, such 
as fatigue, cold intolerance, mental sluggishness, and dry 
skin.[122] A case of myxoedema coma occurring during long- 
term Amiodarone therapy has been reported.[131] In patients 
already on T4 replacement therapy, the dose of T4 may need 
to be increased to slow down the generation of T3 from T4 
induced by Amiodarone. 
Laboratory findings are similar to those in spontaneous 
hypothyroidism, such a decreased serum free T4 and in-
creased serum TSH concentrations. However, high TSH 
levels are not useful in the first three months of Amiodarone 
therapy because are common features related to the medica-
tion. Serum TSH values > 20 mIU/L are commonly seen in 
patients with AIH but rarely in euthyroid patients early in the 
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course of treatment.[13] Serum thyroglobulin is often in-
creased, probably related to the increased thyroid stimulation 
by TSH. The presence of circulating thyroid peroxidase anti-
bodies increased the risk of permanent hypothyroidism.[122] 
3.10.3  Treatment 
If it is necessary to continue Amiodarone for the under-
lying cardiac disorder, it can be continued in association 
with L-T4 replacement, given only once-daily administra-
tion. T4 replacement is almost always considered for pa-
tients with TSH > 20 mU/L.[128] If discontinuation of Amio-
darone therapy is feasible, spontaneous remission of hypo-
thyroidism often occurs, particularly in patients without 
underlying thyroid abnormalities, while this outcome is less 
likely to occur in patients with Hashimoto’s thyroiditis. The 
dose of T4 needed to normalize serum TSH may be higher 
in Amiodarone-treated patients, compared with conven-
tional hypothyroid patients, an event that can be explained 
by Amiodarone-dependent inhibition of pituitary type 2 
5-deiodinase intra-pituitary with a consequent decrease in 
T3 production.[13]  
3.11  Amiodarone and the Syndrome of Inappropriate 
Antidiuretic Hormone Secretion (SIADH) 
SIADH is a rare but serious side effect of Amiodarone 
treatment, which physicians should be aware of particularly 
after the loading dose.[132] Amiodarone-induced SIADH may 
occur during the initial loading period and may be counter-
acted by reducing the dose without discontinuing the drug. 
The mechanism of this adverse drug reaction is not 
known and could involve the channel modulating properties 
of Amiodarone at renal or brain level.[133] There is a clear 
temporal and dose-related association between hyponatre-
mia and the loading phase, therefore serum electrolyte 
monitoring is mandatory during Amiodarone loading, and 
with some regularity thereafter. When SIADH occurs, 
Amiodarone dose must be reduced at first glance or other-
wise discontinued to bring sodium level into normal 
range.[134,135] 
Identifying the exact cause of hyponatremia often is dif-
ficult. Most drugs that cause SIADH act by sensitizing the 
kidney and/or stimulating the release of antidiuretic hor-
mone.[136] Whether Amiodarone acts by one of these 
mechanisms is not known. Hyponatremia resolves rapidly 
within 3–5 days after Amiodarone discontinuation, which is 
surprising because of the long half-life of Amiodarone.  
4  Conclusions 
Amiodarone is one of the most effective antiarrhythmic 
drugs but unfortunately carries a high toxicity profile. Ad-
verse Amiodarone reactions—which involve different or-
gans, including lung, thyroid, eye, and liver, can be life- 
threatening and pose challenges when Amiodarone is used 
to prevent ventricular arrhythmias and there are no alterna-
tive options. On the other hand, Amiodarone is widely pre-
scribed in the elderly for the high incidence of AF in this 
population, notwithstanding there is no support from the 
current guidelines.   
Being the elderly population at risk for adverse drug re-
actions, the choice of introducing Amiodarone in the geriat-
ric population has, therefore, to be cautiously evaluated by 
internal medicine and geriatric specialist doctors, consider-
ing long and short-term side effects, interaction with other 
drugs and patient compliance. 
It’s advisable that patients under Amiodarone treatment 
are strictly monitored to intercept any potential insurgent 
side effects. 
Additional data are needed to evaluate the impact of the 
rarest side effects reported in the literature to fully under-
stand its benefits and disadvantages.  
Acknowledgements 
This work was supported in part by Sapienza University 
grant # C26A15M78W (to IL). 
 
References 
1  Raviña T, Gutierrez J. Amiodarone-induced AV block and 
ventricular standstill. A forme fruste of an idiopathic long QT 
syndrome. Int J Cardiol 2000; 75: 105–108. 
2  Rabinovitz H, Berkowitch M, Golik A, Shani S. [Adverse 
drug reactions definitions and terminology]. Harefuah 2001; 
140: 1181–1186, 1228. [Article in Hebrew]. 
3  Moore TJ, Cohen MR, Furberg CD. Serious adverse drug 
events reported to the Food and Drug Administration, 1998– 
2005. Arch Intern Med 2007; 167: 1752–1759. 
4  Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug 
events in hospitalized patients. Excess length of stay, extra 
costs, and attributable mortality. JAMA 1997; 277: 301–306.  
5  Pirmohamed M, James S, Meakin S, et al. Adverse drug reac-
tions as cause of admission to hospital: prospective analysis of 
18820 patients. BMJ 2004; 329: 15–19. 
6  Schurig AM, Böhme M, Just KS, et al. Adverse Drug Reac-
tions (ADR) and emergencies. Dtsch Arztebl Int 2018; 115: 
251–258. 
7  Ognibene S, Vazzana N, Giumelli C, et al. Hospitalisation and 
morbidity due to adverse drug reactions in elderly patients: a 
single-centre study. Intern Med J 2018; 48: 1192–1197. 
8  Doyle JF, Ho KM. Benefits and risks of long-term amiodar-
one therapy for persistent atrial fibrillation: a meta-analysis. 
Biancatelli RMC, et al. Amiodarone side effects 563 
  
http://www.jgc301.com; jgc@jgc301.com | Journal of Geriatric Cardiology  
Mayo Clin Proc 2009; 84: 234–242. 
9  World Health Organization. Trace elements in human nutri-
tion and health. Geneva: Macmillian Ceuterick 1996; p62. 
10  Martino E, Bartalena L, Bogazzi F, Braverman LE. The ef-
fects of amiodarone on the thyroid. Endocr Rev 2001; 22: 
240–254. 
11  Hrudikova Vyskocilova E, Grundmann M, et al. Therapeutic 
monitoring of amiodarone: pharmacokinetics and evaluation 
of the relationship between effect and dose/concentration. 
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 
2017; 161: 134–143.  
12  Meng X, Mojaverian P, Doedee M, et al. Bioavailability of 
amiodarone tablets administered with and without food in 
healthy subjects. Am J Cardiol 2001; 87: 432–435. 
13  Basaria S, Cooper DS. Amiodarone and the thyroid. Am J 
Med 2005; 118: 706–714. 
14  Aronow WS. Management of the older person with atrial 
fibrillation. J Gerontol A Biol Sci Med Sci 2002; 57: M352– 
M363. 
15  Soyama A, Hanioka N, Saito Y, et al. Amiodarone N-deethy-
lation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 
P404A. Pharmacol Toxicol 2002; 91: 174–178. 
16  Torres-Arraut E, Singh S, Pickoff AS. Electrophysiologic 
effects of tween 80 in the myocardium and specialized con-
duction system of the canine heart. J Electrocardiol 1984; 17: 
145–151. 
17  Veronese ME, McLean S, Hendriks R. Plasma protein binding 
of amiodarone in a patient population: measurement by 
erythrocyte partitioning and a novel glass-binding method. Br 
J Clin Pharmacol 1988; 26: 721–731. 
18  Bohets H, Lavrijsen K, Hendrickx J, et al. Identification of the 
cytochrome P450 enzymes involved in the metabolism of 
cisapride: in vitro studies of potential co-medication inter-
actions. Br J Pharmacol 2000; 129: 1655–1667. 
19  Sanoski CA, Bauman JL. Clinical observations with the 
amiodarone/warfarin interaction: dosing relationships with 
long-term therapy. Chest 2002; 121: 19–23. 
20  Hori R, Okamura N, Aiba T, Tanigawara Y. Role of P-glyco-
protein in renal tubular secretion of digoxin in the isolated 
perfused rat kidney. J Pharmacol Exp Ther 1993; 266: 1620– 
1625. 
21  Amiodarone—FDA prescribing information, side effects and 
uses’. https://www.drugs.com/ pro/amiodarone.html (Accessed 
August 9, 2018). 
22  Epstein AE, Olshansky B, Naccarelli GV, et al. Practical 
management guide for clinicians who treat patients with 
amiodarone. Am J Med 2016; 129: 468–475. 
23  Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of 
low-dose amiodarone in severe congestive heart failure. 
Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca 
en Argentina (GESICA). Lancet 1994; 344: 493–498. 
24  Garguichevich JJ, Ramos, J L, Gambarte A, et al. Effect of 
amiodarone therapy on mortality in patients with left ven-
tricular dysfunction and asymptomatic complex ventricular 
arrhythmias: Argentine Pilot Study of Sudden Death and 
Amiodarone (EPAMSA). Am Heart J 1995; 130: 494–500. 
25  Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an im-
plantable cardioverter-defibrillator for congestive heart failure. 
N Engl J Med 2005; 352: 225–237. 
26  Zipes DP, Prystowsky EN, Heger JJ. Amiodarone: electrophy-
siologic actions, pharmacokinetics and clinical effects. J Am 
Coll Cardiol 1984; 3: 1059–1071. 
27  January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS 
guideline for the management of patients with atrial fibrilla-
tion: executive summary: a report of the American College of 
Cardiology/American Heart Association Task Force on prac-
tice guidelines and the Heart Rhythm Society. Circulation 
2014; 130: 2071–2104. 
28  Chatterjee S, Sardar P, Mukherjee D, et al. Timing and route 
of amiodarone for prevention of postoperative atrial fibrilla-
tion after cardiac surgery: a network regression meta-analysis. 
Pacing Clin Electrophysiol 2013; 36: 1017–1023. 
29  Dohadwala M, Kamili F, Estes NM, Homoud M. Atrioven-
tricular block and pause-dependent torsade de pointes. Hear-
tRhythm Case Rep 2017; 3: 115–119. 
30  Van Mieghem W, Coolen L, Malysse I, et al. Amiodarone 
and the development of ARDS after lung surgery. Chest 1994; 
105: 1642–1645. 
31  Anastasiou-Nana MI, Nanas JN, Nanas SN, et al. Effects of 
amiodarone on refractory ventricular fibrillation in acute 
myocardial infarction: experimental study. J Am Coll Cardiol 
1994; 23: 253–258. 
32  Galve E, Rius T, Ballester R, et al. Intravenous amiodarone in 
treatment of recent-onset atrial fibrillation: results of a ran-
domized, controlled study. J Am Coll Cardiol 1996; 27: 
1079–1082. 
33  Alawami M, Chatfield A, Ghashi R, Walker L. Atrial fibrillation 
after cardiac surgery: prevention and management: the Au-
stralasian experience. J Saudi Heart Assoc 2018; 30: 40–46. 
34  Cordarone (Amiodarone Hydrochloride)—Drug Interactions, 
Contraindications, Other Rx Info. http://www.druglib.com/ 
druginfo/cordarone/interactions_overdosage_contraindications/ 
(Accessed August 9, 2018)  
35  Nafrialdi N, Kurniawan TG, Setiawati A, Makmun LH. QT 
interval prolongation associated with amiodarone use in Cipto 
Mangunkusumo Hospital, Jakarta. Acta Med Indones 2014; 46: 
292–297. 
36  Stramba-Badiale M, Locati EH, Martinelli A, et al. Gender 
and the relationship between ventricular repolarization and 
cardiac cycle length during 24-h Holter recordings. Eur Heart 
J 1997; 18: 1000–1006. 
37  Lim HE, Pak HN, Ahn JC, et al. Torsade de pointes induced 
by short-term oral amiodarone therapy. Europace 2006; 8: 
1051–1053. 
38  Hoffmann C, Falzone E, Augé M, et al. Long QT syndrome, 
amiodarone use, and the mechanism underlying lidocaine 
564 Biancatelli RMC, et al. Amiodarone side effects 
 
http://www.jgc301.com; jgc@jgc301.com | Journal of Geriatric Cardiology 
toxicity. Anesth Analg 2012; 115: 1253–1254. 
39  Antonelli D, Atar S, Freedberg NA, Rosenfeld T. Torsade de 
pointes in patients on chronic amiodarone treatment: contri-
buting factors and drug interactions. Isr Med Assoc J 2005; 7: 
163–165. 
40  Doshi D, Jayawardana R. Amiodarone-induced life-threatening 
refractory hypotension. Am J Case Rep 2015; 16: 617–620. 
41  Ingram DV, Jaggarao NS, Chamberlain DA. Ocular changes 
resulting from therapy with amiodarone. Br J Ophthalmol 
1982; 66: 676–679. 
42  Shukla R, Jowett NI, Thompson DR, Pohl JE. Side effects 
with amiodarone therapy. Postgrad Med J 1994; 70: 492–498. 
43  Park HS, Kim YN. Adverse effects of long-term amiodarone 
therapy. Korean J Intern Med 2014; 29: 571–573. 
44  Mäntyjärvi M, Tuppurainen K, Ikäheimo K. Ocular side ef-
fects of amiodarone. Surv Ophthalmol 1998; 42: 360–366. 
45  Rucker JC, Biousse V, Newman NJ. Ischemic optic neuro-
pathies. Curr Opin Neurol 2004; 17: 27–35. 
46  Mindel JS, Anderson J, Johnson G, et al. Absence of bilateral 
vision loss from amiodarone: a randomized trial. Am Heart J 
2007; 153: 837–842. 
47  Passman RS, Bennett CL, Purpura JM, et al. Amiodarone- 
associated optic neuropathy: a critical review. Am J Med 2012; 
125: 447–453. 
48  Mansour AM, Puklin JE, O’Grady R. Optic nerve ultra-
structure following amiodarone therapy. J Clin Neurooph-
thalmol 1988; 8: 231–237. 
49  Abarbanel JM, Osiman A, Frisher S, Herishanu Y. Peripheral 
neuropathy and cerebellar syndrome associated with amio-
darone therapy. Isr J Med Sci 1987; 23: 893–895. 
50  Costa-Jussà FR, Jacobs JM. The pathology of amiodarone 
neurotoxicity. II. Peripheral neuropathy in man. Brain 1985; 
108: 753–769. 
51  Beck RW, Servais GE, Hayreh SS. Anterior ischemic optic 
neuropathy. IX. Cup-to-disc ratio and its role in pathogenesis. 
Ophthalmology 1987; 94: 1503–1508. 
52  Johnson LN, Krohel GB, Thomas ER. The clinical spectrum 
of amiodarone-associated optic neuropathy. J Natl Med Assoc 
2004; 96: 1477–1491. 
53  Venkatesh N, Singh BN, Al-Sarraf L, Kannan R. Digoxin- 
desethylamiodarone interaction in the rat: comparison with the 
effects of amiodarone. J Cardiovasc Pharmacol 1986; 8: 
309–313. 
54  Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 
AHA/ACC/HRS guideline for management of patients with 
ventricular arrhythmias and the prevention of sudden cardiac 
death: Executive summary: A Report of the American College 
of Cardiology/American Heart Association Task Force on 
Clinical Practice Guidelines and the Heart Rhythm Society. 
Heart Rhythm 2018; 15: e190–e252. 
55  Rotmensch HH, Liron M, Tupilski M, Laniado S. Possible 
association of pneumonitis with amiodarone therapy. Am 
Heart J 1980; 100: 412–413. 
56  Sobol SM, Rakita L. Pneumonitis and pulmonary fibrosis 
associated with amiodarone treatment: a possible complica-
tion of a new antiarrhythmic drug. Circulation 1982; 65: 
819–824. 
57  Rotmensch, HH, Belhassen B, Swanson BN, et al. Steady- 
state serum amiodarone concentrations: relationships with an-
tiarrhythmic efficacy and toxicity. Ann Intern Med 1984; 101: 
462–469. 
58  Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can 
Respir J 2009; 16: 43–48. 
59  Martin WJ, Rosenow EC. Amiodarone pulmonary toxicity. 
Recognition and pathogenesis (Part 2). Chest 1988; 93: 
1242–1248. 
60  Jessurun GA, Crijns HJ. Amiodarone pulmonary toxicity. 
BMJ 1997; 314: 619–620. 
61  Sunderji R, Kanji Z, Gin K. Pulmonary effects of low dose 
amiodarone: a review of the risks and recommendations for 
surveillance. Can J Cardiol 2000; 16: 1435–1440. 
62  Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical 
guide for clinicians who treat patients with amiodarone: 2007. 
Heart Rhythm 2007; 4: 1250–1259. 
63  Polkey MI, Wilson PO, Rees PJ. Amiodarone pneumonitis: no 
safe dose. Respir Med 1995; 89: 233–235. 
64  Ott MC, Khoor A, Leventhal JP, et al. Pulmonary toxicity in 
patients receiving low-dose amiodarone. Chest 2003; 123: 
646–651. 
65  Karnatovskaia LV, Festic E, Gajic O, et al. Prehospital amio-
darone may increase the incidence of acute respiratory distress 
syndrome among patients at risk. J Crit Care 2012; 27: 
447–453. 
66  Sauler M. Gulati M. Newly recognized occupational and en-
vironmental causes of chronic terminal airways and paren-
chymal lung disease. Clin Chest Med 2012; 33: 667–680. 
67  Jackevicius CA, Tom A, Essebag V, et al. Population-level 
incidence and risk factors for pulmonary toxicity associated 
with amiodarone. Am J Cardiol 2011; 108: 705–710. 
68  Holt DW, Tucker GT, Jackson PR, Storey GC. Amiodarone 
pharmacokinetics. Am Heart J 1983; 106: 840–847. 
69  Kratz A, Lewandrowski KB. Case records of the Massa-
chusetts General Hospital. Weekly clinicopathological exer-
cises. Normal reference laboratory values. N Engl J Med 1998; 
339: 1063–1072. 
70  Kennedy JI, Myers JL, Plumb VJ, Fulmer JD. Amiodarone 
pulmonary toxicity. Clinical, radiologic, and pathologic cor-
relations. Arch Intern Med 1987; 147: 50–55. 
71  Coudert B, Bailly F, Lombard JN, et al. Amiodarone pneu-
monitis. Bronchoalveolar lavage findings in 15 patients and 
review of the literature. Chest 1992; 102: 1005–1012. 
72  Marchlinski FE, Gansler TS, Waxman HL, Josephson ME. 
Amiodarone pulmonary toxicity. Ann Intern Med 1982; 97: 
839–845. 
73  Camus P, Martin WJ, Rosenow EC. Amiodarone pulmonary 
toxicity. Clin Chest Med 2004; 25: 65–75. 
74  Endoh Y, Hanai R, Uto K, et al. [Diagnostic usefulness of 
KL-6 measurements in patients with pulmonary complications 
Biancatelli RMC, et al. Amiodarone side effects 565 
  
http://www.jgc301.com; jgc@jgc301.com | Journal of Geriatric Cardiology  
after administration of amiodarone]. J Cardiol 2000; 35: 
121–127. 
75  Singh S, Fletcher RD, Fisher S, et al. Congestive heart failure: 
survival trial of antiarrhythmic therapy (CHF STAT). The 
CHF STAT Investigators. Control Clin Trials 1992; 13: 
339–350. 
76  Sweidan AJ, Singh NK, Dang N, et al. Amiodarone-induced 
pulmonary toxicity—a frequently missed complication. Clin 
Med Insights Case Rep 2016; 9: 91–94. 
77  Kuhlman JE, Teigen C, Ren H, et al. Amiodarone pulmonary 
toxicity: CT findings in symptomatic patients. Radiology 1990; 
177: 121–125. 
78  Zhu YY, Botvinick E, Dae M, et al. Gallium lung scinti-
graphy in amiodarone pulmonary toxicity. Chest 1988; 93: 
1126–1131. 
79  Jarand J, Lee A, Leigh R. Amiodaronoma: an unusual form of 
amiodarone-induced pulmonary toxicity. CMAJ 2007; 176: 
1411–1413. 
80  Azzam I, Tov N, Elias N, Naschitz JE. Amiodarone toxicity 
presenting as pulmonary mass and peripheral neuropathy: the 
continuing diagnostic challenge. Postgrad Med J 2006; 82: 
73–75. 
81  Halley A, Hugentobler A, Icard P, et al. Efficiency of 18F- 
FDG and 99mTc-depreotide SPECT in the diagnosis of ma-
lignancy of solitary pulmonary nodules. Eur J Nucl Med Mol 
Imaging 2005; 32: 1026–1032. 
82  Ashrafian H, Davey P. Is amiodarone an underrecognized 
cause of acute respiratory failure in the ICU? Chest 2001; 120: 
275–282. 
83  Schwaiblmair M, Berghaus T, Haeckel T, et al. Amio-
darone-induced pulmonary toxicity: an under-recognized and 
severe adverse effect? Clin Res Cardiol 2010; 99: 693–700. 
84  Gleadhill IC, Wise RA, Schonfeld SA, et al. Serial lung func-
tion testing in patients treated with amiodarone: a prospective 
study. Am J Med 1989; 86: 4–10. 
85  Reyes CV, Thompson KS, Jensen J. Multivesiculated macro-
phages: their implication in fine-needle aspiration cytology of 
lung mass lesions. Diagn. Cytopathol 1998; 19: 98–101. 
86  Dusman RE, Stanton MS, Miles WM, et al. Clinical features 
of amiodarone-induced pulmonary toxicity. Circulation 1990; 
82: 51–59. 
87  Okayasu K, Takeda Y, Kojima J, et al. Amiodarone pulmo-
nary toxicity: a patient with three recurrences of pulmonary 
toxicity and consideration of the probable risk for relapse. In-
tern Med 2006; 45: 1303–1307. 
88  Zaher C, Hamer A, Peter T, Mandel W. Low-dose steroid 
therapy for prophylaxis of amiodarone-induced pulmonary in-
filtrates. N Engl J Med 1983; 308: 779. 
89  Vernhet H, Bousquet C, Durand G, et al. Reversible amio-
darone-induced lung disease: HRCT findings. Eur Radiol 
2001; 11: 1697–1703. 
90  Iskandar SB, Abi-Saleh B, Keith RL, et al. Amiodarone- in-
duced alveolar hemorrhage. South Med J 2006; 99: 383–387. 
91  Lewis JH, Ranard RC, Caruso A, et al. Amiodarone hepato-
toxicity: prevalence and clinicopathologic correlations among 
104 patients. Hepatology 1989; 9: 679–685. 
92  Guigui B, Perrot S, Berry JP, et al. Amiodarone-induced he-
patic phospholipidosis: a morphological alteration indepen-
dent of pseudoalcoholic liver disease. Hepatology 1988; 8: 
1063–1068. 
93  Desai AD, Chun S, Sung RJ. The role of intravenous amio-
darone in the management of cardiac arrhythmias. Ann Intern 
Med 1997; 127: 294–303. 
94  Gluck N, Fried M, Porat R. Acute amiodarone liver toxicity 
likely due to ischemic hepatitis. Isr Med Assoc J 2011; 13: 
748–752. 
95  Lahbabi M. Acute hepatitis secondary to parenteral amio-
darone does not preclude subsequent oral therapy. World J 
Hepatol 2012; 4: 196. 
96  Rätz Bravo AE, Drewe J, Schlienger RG, et al. Hepatotoxicity 
during rapid intravenous loading with amiodarone: Descrip-
tion of three cases and review of the literature. Crit Care Med 
2005; 33: 128–34, discussion 245. 
97  Chen CC, Wu CC. Acute hepatotoxicity of intravenous amio-
darone: case report and review of the literature. Am J Ther 
2016; 23: e260–e263. 
98  Enseleit F, Wyss CA, Duru F, et al. Images in cardiovascular 
medicine. The blue man: amiodarone-induced skin discolora-
tion. Circulation 2006; 113: e63. 
99  Collins P, Ferguson J. Narrow-band UVB (TL-01) photo-
therapy: an effective preventative treatment for the photoder-
matoses. Br J Dermatol 1995; 132: 956–963. 
100  Jaworski K, Walecka I, Rudnicka L, et al. Cutaneous adverse 
reactions of amiodarone. Med Sci Monit 2014; 20: 
2369–2372. 
101  Dootson G, Byatt C. Amiodarone-induced vasculitis and a 
review of the cutaneous side-effects of amiodarone. Clin Exp 
Dermatol 1994; 19: 422–424. 
102  Korantzopoulos P, Kyrlas K, Goudevenos JA. Amio-
darone-induced hair loss: case report and review of the litera-
ture. QJM 2015; 108: 325–327. 
103  Samanta A, Jones GR, Burden AC. Adverse reactions during 
treatment with amiodarone hydrochloride. Br Med J (Clin Res 
Ed) 1983; 287: 503. 
104  Ahmad S. Amiodarone and reversible alopecia. Arch Intern 
Med 1995; 155: 1106. 
105  Gasparich JP, Mason JT, Greene HL, et al. Amiodarone- 
associated epididymitis: drug-related epididymitis in the ab-
sence of infection. J Urol 1985; 133: 971–972. 
106  Hamoud K, Kaneti J, Smailowitz Z, Lissmer L. Amiodar-
one-induced epididymitis. Report of 2 cases. Eur Urol 1996; 
29: 497–498. 
107  Sadek I, Biron P, Kus T. Amiodarone-induced epididymitis: 
report of a new case and literature review of 12 cases. Can J 
Cardiol 1993; 9: 833–836. 
108  Kirkali Z. Recurrent bilateral amiodarone induced epididy-
mitis. J Urol 1999; 162: 808–809. 
566 Biancatelli RMC, et al. Amiodarone side effects 
 
http://www.jgc301.com; jgc@jgc301.com | Journal of Geriatric Cardiology 
109  Yamreudeewong W, McIntyre WW, Sun TJ, Ranelli PL. 
Bone marrow granulomas possibly associated with amiodar-
one. Pharmacotherapy 2000; 20: 855–859. 
110  Mohamed T, Sanjay R, Sycheva T, et al. Amiodarone-asso-
ciated bone marrow granulomas: a report of 2 cases and re-
view of the literature. Int J Hematol 2007; 85: 101–104. 
111  Mukhopadhyay S, Mukhopadhyay S, Abraham NZ, et al. 
Unexplained bone marrow granulomas: Is amiodarone the 
culprit? A report of 2 cases. World J Hepatol 2004; 75: 
110–112. 
112  Salouage I, Klouz A, Trabelsi S, et al. Neuro-psychiatric dis-
orders induced by Amiodarone high levels (Cordarone). 
Therapie 2007; 62: 357–359. 
113  Rajagopal S. Catatonic depression precipitated by amiodarone 
prescribed for atrial fibrillation. Ind J Psychiatry 2015; 57: 
105. 
114  Athwal H, Murphy G, Chun S. Amiodarone-induced delirium. 
Am J Geriatr Psychiatry 2003; 11: 696–697.  
115  Barry JJ, Franklin K. Amiodarone-induced delirium. Am J 
Psychiatry 1999; 156: 1119. 
116  Vorperian VR, Havighurst TC, Miller S, January CT. Adverse 
effects of low dose amiodarone: a meta-analysis. J Am Coll 
Cardiol 1997; 30: 791–798. 
117  Flanagan EP, Harper CM, St Louis EK, et al. Amiodarone- 
associated neuromyopathy: a report of four cases: Letter to the 
Editor. Eur J Neurol 2012; 19: e50–e51. 
118  Carella F, Riva E, Morandi L, et al. Myopathy during amio-
darone treatment: a case report. Ital J Neurol Sci 1987; 8: 
605–608.  
119  Narayana SK, Woods DR, Boos CJ. Management of amiodar-
one-related thyroid problems. Ther Adv Endocrinol Metab 
2011; 2: 115–126. 
120  Tsang W, Houlden RL. Amiodarone-induced thyrotoxicosis: 
a review. Can J Cardiol 2009; 25: 421–424. 
121  Eskes SA, Wiersinga WM. Amiodarone and thyroid. Best 
Pract. Res Clin Endocrinol Metab 2009; 23: 735–751. 
122  Han TS, Williams GR, Vanderpump MPJ. Benzofuran de-
rivatives and the thyroid. Clin Endocrinol (Oxf) 2009; 70: 
2–13. 
123  Kurt IH, Yigit T, Karademir BM. Atrial fibrillation due to late 
amiodarone-induced thyrotoxicosis. Clin Drug Investig 2008; 
28: 527–531. 
124  O’Sullivan AJ. Amiodarone-induced thyrotoxicosis: left ven-
tricular dysfunction is associated with increased mortality. 
Eur J Endocrinol 2006; 154: 533–536. 
125  Bogazzi F, Bartalena L, Martino E. Approach to the patient 
with amiodarone-induced thyrotoxicosis. J Clin Endocrinol 
Metab 2010; 95: 2529–2535. 
126  Piga M, Cocco MC, Serra A, et al. The usefulness of 99mTc- 
sestaMIBI thyroid scan in the differential diagnosis and man-
agement of amiodarone-induced thyrotoxicosis. Eur J Endo-
crinol 2008; 159: 423–429. 
127  Bogazzi F, Martino E, Dell’Unto E, et al. Thyroid color flow 
doppler sonography and radioiodine uptake in 55 consecutive 
patients with amiodarone-induced thyrotoxicosis. J Endocri-
nol Invest 2003; 26: 635–640. 
128  Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, 
and pathogenesis of amiodarone-induced thyrotoxicosis and 
hypothyroidism. Am J Med 1991; 91: 507–511. 
129  Bongard V, Marc D, Philippe V, et al. Incidence rate of ad-
verse drug reactions during long-term follow-up of patients 
newly treated with amiodarone. Am J Ther 2006; 13: 315–319. 
130  Martino E, Aghini-Lombardi F, Bartalena L, et al. Enhanced 
susceptibility to amiodarone-induced hypothyroidism in pa-
tients with thyroid autoimmune disease. Arch Intern Med 
1994; 154: 2722–2726. 
131  Mazonson PD, Williams ML, Cantley LK, et al. Myxedema 
coma during long-term amiodarone therapy. Am J Med 1984; 
77: 751–754. 
132  Afshinnia F, Sheth N, Perlman R. Syndrome of inappropriate 
antidiuretic hormone in association with amiodarone therapy: 
a case report and review of literature. Ren Fail 2011; 33: 
456–458. 
133  Pham L, Shaer AJ, Marnejon T. Hyponatremia—a rare but 
serious complication of amiodarone: a case report and review 
of the literature. Case Rep Nephrol Urol 2013; 3: 46–50. 
134  Aslam MK, Gnaim C, Kutnick J, et al. Syndrome of inappro-
priate antidiuretic hormone secretion induced by amiodarone 
therapy. Pacing Clin Electrophysiol 2004; 27: 831–832. 
135  Patel GP, Kasiar JB. Syndrome of inappropriate antidiuretic 
hormone-induced hyponatremia associated with amiodarone. 
Pharmacotherapy 2002; 22: 649–651. 
136  Mulloy AL, Caruana RJ. Hyponatremic emergencies. Med 
Clin North Am 1995; 79: 155–168. 
 
